Ovarian cancer clinical trials indiana

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Patients with platinum-sensitive ovarian cancer in maintenance phase of second-line treatment. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. More Information.

Layout table for additonal information Responsible Party: Genentech, Inc. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. Patient with synchronous high grade serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium is not eligible. Patient receiving radiotherapy within 6 weeks prior to study treatment. Previous allogenic bone marrow transplant. Any previous treatment with PARP inhibitor.

Administration of other simultaneous chemotherapy drugs - except during a HIPEC procedure with cisplatin at PDS, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period hormonal replacement therapy is permitted as are steroid antiemetics.

Clinically significant e. History or evidence of hemorrhagic disorders. Evidence of bleeding diathesis or significant coagulopathy in the absence of coagulation. History or clinical suspicion of brain metastases or spinal cord compression. Spinal MRI is mandatory within 4 weeks prior to randomization in case of suspected spinal cord compression. History or evidence upon neurological examination of central nervous system CNS disease, unless adequately treated with standard medical therapy e.

Significant traumatic injury during 4 weeks prior to randomization. Non-healing wound, active ulcer, or bone fracture. Patient with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection is eligible but require 3 weekly wound examinations. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.

Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.

Pregnant or lactating women. Participation in another clinical study with any intravenous or oral investigational product is not allowed. However, participation in a surgical clinical study including Hyperthermic Chemotherapy HIPEC during the surgical procedure is allowed. Patient unable to swallow orally administered medication and patient with gastrointestinal disorders likely to interfere with absorption of the study medication.

O varian cancer occurs when some cells in your ovaries start to rapidly divide uncontrollably, creating growths or tumors around the ovaries and surrounding tissues. Start Matching. How is Ovarian Cancer Diagnosed? Bloating Indigestion and changes in appetite Changes in bowel movements Urinary incontinence or increased urge to urinate. Pain around the pelvis area Back pain Fatigue. What Causes Ovarian Cancer? These are some risk factors that have been observed in women with ovarian cancer:.

Hormone Replacement Therapy After Menopause. Family History. Being Obese or Overweight. How is Ovarian Cancer Treated? Stage 1 Cancer is still small and contained within one area. We've found. Robert H. Click here to add this to my saved trials. Winship Cancer Institute of Emory University. University of Oklahoma Health Sciences Center.

Women's and Infant's Hospital. Vanderbilt-Ingram Cancer Center. Montefiore Medical Center. Barbara Ann Karmanos Cancer Institute. Brooke Army Medical Center. North Virigina Pelvic Surgery Associates. Medical University of South Carolina Hospital. Chattanooga's Program in Women's Oncology. Florida Center for Gynecologic Oncology. Comprehensive Gynecologic Oncology. NorthShore Medical Group.

University of South Alabama. Women and Infants Hospital of Rhode Island. University of Virginia Cancer Center. Alaska Women's Cancer Care. Northside Hospital. Augusta University Medical Center. Medical Center of Aurora. Greater Baltimore Medical Center. Overlake Hospital Medical Center.